Barclays Issues Positive Forecast for Pacific Biosciences of California (NASDAQ:PACB) Stock Price

Pacific Biosciences of California (NASDAQ:PACB) had its price target lifted by analysts at Barclays from $1.25 to $2.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has an “underweight” rating on the biotechnology company’s stock. Barclays‘s price target would indicate a potential downside of 18.53% from the stock’s current price.

A number of other research analysts also recently issued reports on PACB. Piper Sandler reiterated a “neutral” rating and issued a $3.00 price target (up from $2.00) on shares of Pacific Biosciences of California in a report on Thursday. Weiss Ratings upgraded Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. Wall Street Zen downgraded Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, UBS Group initiated coverage on Pacific Biosciences of California in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $1.35 target price on the stock. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $2.09.

Pacific Biosciences of California Trading Down 3.7%

Shares of PACB traded down $0.10 during mid-day trading on Thursday, hitting $2.46. The company’s stock had a trading volume of 14,948,734 shares, compared to its average volume of 8,316,060. The company’s 50-day moving average is $1.89 and its 200-day moving average is $1.62. Pacific Biosciences of California has a 52-week low of $1.07 and a 52-week high of $3.43. The firm has a market capitalization of $763.09 million, a price-to-earnings ratio of -5.64 and a beta of 2.21.

Pacific Biosciences of California (NASDAQ:PACB) last issued its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. The company had revenue of $40.56 million for the quarter, compared to analyst estimates of $39.31 million. Pacific Biosciences of California had a negative net margin of 82.49% and a negative return on equity of 5,752.12%. As a group, sell-side analysts predict that Pacific Biosciences of California will post -0.52 earnings per share for the current fiscal year.

Insider Activity at Pacific Biosciences of California

In other news, insider James Gibson, II sold 661,815 shares of the firm’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $3.11, for a total value of $2,058,244.65. Following the completion of the sale, the insider owned 1,083,848 shares of the company’s stock, valued at $3,370,767.28. This trade represents a 37.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Van Oene sold 26,911 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1.13, for a total value of $30,409.43. Following the transaction, the insider owned 2,705,853 shares in the company, valued at approximately $3,057,613.89. This trade represents a 0.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Pacific Biosciences of California

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Pacific Biosciences of California in the 2nd quarter valued at approximately $54,330,000. Bank of America Corp DE purchased a new stake in Pacific Biosciences of California during the 2nd quarter worth approximately $2,265,000. Hhlr Advisors LTD. acquired a new position in Pacific Biosciences of California during the 2nd quarter valued at approximately $1,544,000. Bank of New York Mellon Corp acquired a new position in Pacific Biosciences of California during the 2nd quarter valued at approximately $1,290,000. Finally, Man Group plc acquired a new position in Pacific Biosciences of California during the 2nd quarter valued at approximately $1,004,000.

Key Pacific Biosciences of California News

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: PacBio reported a Q3 loss of $0.11 per share, narrower than the $0.13 loss analysts expected, while revenue of $40.56 million topped the $39.31 million consensus. The loss was also slightly smaller than the $0.12 per share reported a year earlier. Zacks Q3 earnings report
• Positive Sentiment: Recent coverage points to clinical adoption and AI partnerships as contributors to steady growth, supporting the longer-term business outlook. Q3 2026 business overview
• Neutral Sentiment: Piper Sandler kept its “neutral” rating but raised its price target to $3 from $2, indicating a higher valuation estimate without a change in its recommendation. Piper Sandler rating information
• Negative Sentiment: PacBio narrowed its 2026 revenue guidance to $155 million–$160 million and is targeting cash-flow breakeven in 2028. The distant breakeven goal underscores that substantial cash-flow improvement remains ahead, despite the quarterly beat. Revenue guidance and breakeven outlook

About Pacific Biosciences of California

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.